May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Combination Submacular Anti-VEGF Therapy and Recombinant Tissue Plasminogen Activator for Management of Massive Submacular Hemorrhage in ARMD
Author Affiliations & Notes
  • S. P. Shah
    Department of Ophthalmology, UCLA - Jules Stein Eye Institute, Los Angeles, California
  • J. Hubschman
    Department of Ophthalmology, UCLA - Jules Stein Eye Institute, Los Angeles, California
  • C. R. Gonzales
    Department of Ophthalmology, UCLA - Jules Stein Eye Institute, Los Angeles, California
  • S. D. Schwartz
    Department of Ophthalmology, UCLA - Jules Stein Eye Institute, Los Angeles, California
  • Footnotes
    Commercial Relationships  S.P. Shah, None; J. Hubschman, None; C.R. Gonzales, None; S.D. Schwartz, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5981. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. P. Shah, J. Hubschman, C. R. Gonzales, S. D. Schwartz; Combination Submacular Anti-VEGF Therapy and Recombinant Tissue Plasminogen Activator for Management of Massive Submacular Hemorrhage in ARMD. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5981. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To retrospectively evaluate combination submacular anti-VEGF therapy and recombinant tissue plasminogen activator (rt-PA) for management of massive submacular hemorrhage in ARMD.

Methods: : Two cases were retrospectively reviewed. Patient’s underwent 25-gauge pars plana vitrectomy, surgical induction of posterior vitreous separation, submacular injection of both rt-PA and anti-VEGF therapy, and 20% SF6 intraocular tamponade. Both patient’s received their first postoperative intravitreous anti-VEGF injection 4-6 weeks after surgery. Pre and post operative findings are reviewed.

Results: : Patient #1An 84 year-old male with known ARMD presented with sudden, painless vision loss to CF at 4 feet and was diagnosed with a fresh, large submacular hemorrhage. He urgently underwent the procedure described above. The hemorrhage was successfully displaced and the visual acuity at last follow up was 20/70. The patient has continued to undergo regular intravitreous anti-VEGF injections. Findings include minimal persistent subretinal fluid and resolved submacular hemorrhage.Patient #2A 77 year-old female with known ARMD and a pigment epithelial detachment presented with sudden, painless vision loss. Preoperative vision was 20/125-2. She urgently underwent the procedure described above. At POM #9, the visual acuity was 20/70-1 with an extrafoveal tear of the retinal pigment epithelium. She has continued to receive regular intravitreous anti-VEGF injections since her surgery.

Conclusions: : Combination submacular anti-VEGF therapy delivered at the time of pars plana vitrectomy and submacular tissue plasminogen activator assisted hemorrhage displacement may be a viable treatment strategy for the management of patients with massive submacular hemorrhage. Prospective evaluation of this strategy may be warranted.

Keywords: vascular endothelial growth factor • vitreoretinal surgery • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×